Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006395. doi: 10.1101/cshperspect.a006395.

Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.

Author information

  • 1University of California, San Diego, California 92093, USA. paisen@ucsd.edu

Abstract

In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-d-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau.

PMID:
22393531
[PubMed - indexed for MEDLINE]
PMCID:
PMC3282492
Free PMC Article

Publication Types, MeSH Terms, Substances, Grant Support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk